TGA criticised over lack of safety warnings Questions have been raised over the way Australia’s therapeutic regulator is informing doctors and patients about potentially dangerous drugs.
Codeine supply in Australia has almost halved The massive decrease has been attributed to the 2018 decision to up-schedule codeine to a Schedule 4 prescription-only medicine.
Why down-scheduling medicines is fraught with danger Assoc Prof Mark Morgan questions whether a push to make more prescription-only medicines available over the counter is best for patients.
It may be ‘natural’, but is it healthy? RACGP supports the TGA’s move to ensure advertising claims of ‘natural’ ingredients in therapeutic goods are not misleading.
Safety concerns over popular arthritis drug The TGA issued an alert after a study found high doses of tofacitinib could lead to increased risk of blood clots in the lungs and potentially death.
TGA moves to ease fears over a ‘no deal’ Brexit Imported medicines and devices will be minimally affected under a ‘no deal’ Brexit, according to the Therapeutic Goods Administration.
Commercial sensitivity or patient protection? Secrecy and medicine safety Researchers have identified an information gap between pharmacological companies and Australian clinicians on the potential safety risks of medicines.
The good, the bad and the dangerous: Advising on healthcare apps How can GPs and patients distinguish the helpful from the useless – or even harmful – among the ever-increasing flood of healthcare apps?
TGA changes offer greater protection from misleading advertising The TGA intends its updated code to provide consumers improved protection from misleading advertising of therapeutic goods.
Greg Hunt proposes changes to reporting scheme to help address medicine shortages The Federal Health Minister wants to make the reporting scheme mandatory rather than voluntary, with legal definitions of medicine shortage and penalties for non-compliance.